Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden

Research output: Contribution to journalArticle

Standard

Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden. / Granstam, Elisabet; Westborg, Inger; Barkander, Anna; Börjesson, Malin; Lindahl, Sara; Meszaros, Eva; Wojciechowska-Zajac, Anna; Wagner, Philippe; Albrecht, Susanne; Karlsson, Niklas; Bjärnhall, Gunilla; Lövestam, Adrian Monica.

In: Acta Ophthalmologica, Vol. 94, No. 7, 01.11.2016, p. 646-651.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

Granstam, Elisabet ; Westborg, Inger ; Barkander, Anna ; Börjesson, Malin ; Lindahl, Sara ; Meszaros, Eva ; Wojciechowska-Zajac, Anna ; Wagner, Philippe ; Albrecht, Susanne ; Karlsson, Niklas ; Bjärnhall, Gunilla ; Lövestam, Adrian Monica. / Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden. In: Acta Ophthalmologica. 2016 ; Vol. 94, No. 7. pp. 646-651.

RIS

TY - JOUR

T1 - Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration – a population- and register-based study from northern Sweden

AU - Granstam, Elisabet

AU - Westborg, Inger

AU - Barkander, Anna

AU - Börjesson, Malin

AU - Lindahl, Sara

AU - Meszaros, Eva

AU - Wojciechowska-Zajac, Anna

AU - Wagner, Philippe

AU - Albrecht, Susanne

AU - Karlsson, Niklas

AU - Bjärnhall, Gunilla

AU - Lövestam, Adrian Monica

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose: To study the occurrence of severe visual impairment (SVI) and treatment outcome at 12 months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties. Methods: Referrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12 months from the SMR database from 2008 until 2013 in patients >65 years of age in five northern counties were included in the survey. Results: The rate of referral due to AMD was significantly reduced during the time period (−48%; p < 0.001). At 12 months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (−0.01, SD 0.37; p < 0.001) after a mean of 5.0 ± 2.3 anti-vascular endothelial growth factor (VEGF)-injections were administered. Age and low baseline VA was associated with less favourable visual outcome (p < 0.001). Conclusion: Referral rate to low vision clinic is a valuable tool for estimating occurrence of SVI and fell between the years 2005 until 2013. Data from the SMR showed improvement in visual acuity on the whole, but also identified patients at high risk for developing SVI during anti-VEGF-treatment.

AB - Purpose: To study the occurrence of severe visual impairment (SVI) and treatment outcome at 12 months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties. Methods: Referrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12 months from the SMR database from 2008 until 2013 in patients >65 years of age in five northern counties were included in the survey. Results: The rate of referral due to AMD was significantly reduced during the time period (−48%; p < 0.001). At 12 months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (−0.01, SD 0.37; p < 0.001) after a mean of 5.0 ± 2.3 anti-vascular endothelial growth factor (VEGF)-injections were administered. Age and low baseline VA was associated with less favourable visual outcome (p < 0.001). Conclusion: Referral rate to low vision clinic is a valuable tool for estimating occurrence of SVI and fell between the years 2005 until 2013. Data from the SMR showed improvement in visual acuity on the whole, but also identified patients at high risk for developing SVI during anti-VEGF-treatment.

KW - anti-vascular endothelial growth factor

KW - low vision clinics

KW - Swedish Macula Register

KW - wet AMD

UR - http://www.scopus.com/inward/record.url?scp=84991585512&partnerID=8YFLogxK

U2 - 10.1111/aos.13187

DO - 10.1111/aos.13187

M3 - Article

VL - 94

SP - 646

EP - 651

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-3768

IS - 7

ER -